miRNA profiling of biliary intraepithelial neoplasia reveals stepwise tumorigenesis in distal cholangiocarcinoma via the miR-451a/ATF2 axis.


Journal

The Journal of pathology
ISSN: 1096-9896
Titre abrégé: J Pathol
Pays: England
ID NLM: 0204634

Informations de publication

Date de publication:
11 2020
Historique:
received: 19 12 2019
revised: 30 05 2020
accepted: 17 07 2020
pubmed: 28 7 2020
medline: 18 12 2020
entrez: 26 7 2020
Statut: ppublish

Résumé

Distal cholangiocarcinoma (dCCA) is a biliary tract cancer with a dismal prognosis and is often preceded by biliary intraepithelial neoplasia (BilIN), representing the most common biliary non-invasive precursor lesion. BilIN are histologically well defined but have not so far been characterised systematically at the molecular level. The aim of this study was to determine miRNA-regulated genes in cholangiocarcinogenesis via BilIN. We used a clinicopathologically well-characterised cohort of 12 dCCA patients. Matched samples of non-neoplastic biliary epithelia, BilIN and invasive tumour epithelia of each patient were isolated from formalin-fixed paraffin-embedded tissue sections by laser microdissection. The resulting 36 samples were subjected to total RNA extraction and the expression of 798 miRNAs was assessed using the Nanostring® technology. Candidate miRNAs were validated by RT-qPCR and functionally investigated following lentiviral overexpression in dCCA-derived cell lines. Potential direct miRNA target genes were identified by microarray and prediction algorithms and were confirmed by luciferase assay. We identified 49 deregulated miRNAs comparing non-neoplastic and tumour tissue. Clustering of these miRNAs corresponded to the three stages of cholangiocarcinogenesis, supporting the concept of BilIN as a tumour precursor. Two downregulated miRNAs, i.e. miR-451a (-10.9-fold down) and miR-144-3p (-6.3-fold down), stood out by relative decrease. Functional analyses of these candidates revealed a migration inhibitory effect in dCCA cell lines. Activating transcription factor 2 (ATF2) and A disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) were identified as direct miR-451a target genes. Specific ATF2 inhibition by pooled siRNAs reproduced the inhibitory impact of miR-451a on cancer cell migration. Thus, our data support the concept of BilIN as a direct precursor of invasive dCCA at the molecular level. In addition, we identified miR-451a and miR-144-3p as putative tumour suppressors attenuating cell migration by inhibiting ATF2 in the process of dCCA tumorigenesis. © The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.

Identifiants

pubmed: 32710569
doi: 10.1002/path.5514
doi:

Substances chimiques

ATF2 protein, human 0
Activating Transcription Factor 2 0
Biomarkers, Tumor 0
MIRN144 microRNA, human 0
MIRN451 microRNA, human 0
Membrane Proteins 0
MicroRNAs 0
Amyloid Precursor Protein Secretases EC 3.4.-
ADAM10 Protein EC 3.4.24.81
ADAM10 protein, human EC 3.4.24.81

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

239-251

Informations de copyright

© The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.

Références

Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016; 13: 261-280.
Kendall T, Verheij J, Gaudio E, et al. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int 2019; 39(Suppl1): 7-18.
Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-532.
Reid BJ, Barrett MT, Galipeau PC, et al. Barrett's esophagus: ordering the events that lead to cancer. Eur J Cancer Prev 1996; 5(Suppl2): 57-65.
Valenzuela M, Julian TB. Ductal carcinoma in situ: biology, diagnosis, and new therapies. Clin Breast Cancer 2007; 7: 676-681.
Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001; 25: 579-586.
Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 2019; 76: 182-188.
Mertens JC, Rizvi S, Gores GJ. Targeting cholangiocarcinoma. Biochim Biophys Acta 2018; 1864(4 Pt B): 1454-1460.
Hsu M, Sasaki M, Igarashi S, et al. KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas. Cancer 2013; 119: 1669-1674.
Nakanuma Y, Sasaki M, Sato Y, et al. Multistep carcinogenesis of perihilar cholangiocarcinoma arising in the intrahepatic large bile ducts. World J Hepatol 2009; 1: 35-42.
Itatsu K, Zen Y, Ohira S, et al. Immunohistochemical analysis of the progression of flat and papillary preneoplastic lesions in intrahepatic cholangiocarcinogenesis in hepatolithiasis. Liver Int 2007; 27: 1174-1184.
Sato Y, Harada K, Sasaki M, et al. Histological characterization of biliary intraepithelial neoplasia with respect to pancreatic intraepithelial neoplasia. Int J Hepatol 2014; 2014: 678260.
Walter D, Herrmann E, Winkelmann R, et al. Role of CD15 expression in dysplastic and neoplastic tissue of the bile duct - a potential novel tool for differential diagnosis of indeterminate biliary stricture. Histopathology 2016; 69: 962-970.
Bergquist A, Seth E. Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol 2015; 29: 221-232.
Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011; 12: 861-874.
Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838.
Svoronos AA, Engelman DM, Slack FJ. OncomiR or tumor suppressor? The duplicity of microRNAs in cancer. Cancer Res 2016; 76: 3666-3670.
Salati M, Braconi C. Noncoding RNA in cholangiocarcinoma. Semin Liver Dis 2019; 39: 13-25.
Puik JR, Meijer LL, Le Large TY, et al. miRNA profiling for diagnosis, prognosis and stratification of cancer treatment in cholangiocarcinoma. Pharmacogenomics 2017; 18: 1343-1358.
Merino-Azpitarte M, Lozano E, Perugorria MJ, et al. SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma. J Hepatol 2017; 67: 72-83.
Hannus M, Beitzinger M, Engelmann JC, et al. siPools: highly complex but accurately defined siRNA pools eliminate off-target effects. Nucleic Acids Res 2014; 42: 8049-8061.
R Core Team. R: A Language and Environment for Statistical Computing [Internet]. R Foundation for Statistical Computing; Vienna, 2017; [Accessed 20 November 2019]. Available from: https://www.R-project.org/.
Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015; 43: e47.
Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988; 75: 800-802.
Schindelin J, Arganda-Carreras I, Frise E, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods 2012; 9: 676-682.
Agarwal V, Bell GW, Nam J-W, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. eLife 2015; 4: e05005.
Dweep H, Gretz N. miRWalk2.0: a comprehensive atlas of microRNA-target interactions. Nat Methods 2015; 12: 697.
Sato Y, Harada K, Sasaki M, et al. Histological characteristics of biliary intraepithelial neoplasia-3 and intraepithelial spread of cholangiocarcinoma. Virchows Arch 2013; 462: 421-427.
Sato Y, Sasaki M, Harada K, et al. Pathological diagnosis of flat epithelial lesions of the biliary tract with emphasis on biliary intraepithelial neoplasia. J Gastroenterol 2014; 49: 64-72.
Bickenbach K, Galka E, Roggin KK. Molecular mechanisms of cholangiocarcinogenesis: are biliary intraepithelial neoplasia and intraductal papillary neoplasms of the bile duct precursors to cholangiocarcinoma? Surg Oncol Clin North Am 2009; 18: 215-224.
Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet 2015; 47: 1003-1010.
Yin Y, Song M, Gu B, et al. Systematic analysis of key miRNAs and related signaling pathways in colorectal tumorigenesis. Gene 2016; 578: 177-184.
Yang R, Chen Y, Tang C, et al. MicroRNA-144 suppresses cholangiocarcinoma cell proliferation and invasion through targeting platelet activating factor acetylhydrolase isoform 1b. BMC Cancer 2014; 14: 917.
Dore LC, Amigo JD, Dos Santos CO, et al. A GATA-1-regulated microRNA locus essential for erythropoiesis. Proc Natl Acad Sci U S A 2008; 105: 3333-3338.
Altuvia Y, Landgraf P, Lithwick G, et al. Clustering and conservation patterns of human microRNAs. Nucleic Acids Res 2005; 33: 2697-2706.
Berezikov E, Guryev V, van de Belt J, et al. Phylogenetic shadowing and computational identification of human microRNA genes. Cell 2005; 120: 21-24.
Yamada Y, Arai T, Kojima S, et al. Regulation of antitumor miR-144-5p targets oncogenes: direct regulation of syndecan-3 and its clinical significance. Cancer Sci 2018; 109: 2919-2936.
Yang J-S, Maurin T, Robine N, et al. Conserved vertebrate mir-451 provides a platform for Dicer-independent, Ago2-mediated microRNA biogenesis. Proc Natl Acad Sci U S A 2010; 107: 15163-15168.
Gao Z, Zhang P, Xie M, et al. miR-144/451 cluster plays an oncogenic role in esophageal cancer by inhibiting cell invasion. Cancer Cell Int 2018; 18: 184.
Babapoor S, Fleming E, Wu R, et al. A novel miR-451a isomiR, associated with amelanotypic phenotype, acts as a tumor suppressor in melanoma by retarding cell migration and invasion. PLoS One 2014; 9: e107502.
Kawai S, Fujii T, Kukimoto I, et al. Identification of miRNAs in cervical mucus as a novel diagnostic marker for cervical neoplasia. Sci Rep 2018; 8: 7070.
Xu K, Han B, Bai Y, et al. MiR-451a suppressing BAP31 can inhibit proliferation and increase apoptosis through inducing ER stress in colorectal cancer. Cell Death Dis 2019; 10: 152.
Xiao R, Li C, Chai B. miRNA-144 suppresses proliferation and migration of colorectal cancer cells through GSPT1. Biomed Pharmacother 2015; 74: 138-144.
Cao T, Li H, Hu Y, et al. miR-144 suppresses the proliferation and metastasis of hepatocellular carcinoma by targeting E2F3. Tumour Biol 2014; 35: 10759-10764.
Lv G, Hu Z, Tie Y, et al. MicroRNA-451 regulates activating transcription factor 2 expression and inhibits liver cancer cell migration. Oncol Rep 2014; 32: 1021-1028.
Long J, Xiong J, Bai Y, et al. Construction and investigation of a lncRNA-associated ceRNA regulatory network in cholangiocarcinoma. Front Oncol 2019; 9: 649.
Shen Y-Y, Cui J-Y, Yuan J, et al. MiR-451a suppressed cell migration and invasion in non-small cell lung cancer through targeting ATF2. Eur Rev Med Pharmacol Sci 2018; 22: 5554-5561.
Watson G, Ronai ZA, Lau E. ATF2, a paradigm of the multifaceted regulation of transcription factors in biology and disease. Pharmacol Res 2017; 119: 347-357.
Lau E, Kluger H, Varsano T, et al. PKCε promotes oncogenic functions of ATF2 in the nucleus while blocking its apoptotic function at mitochondria. Cell 2012; 148: 543-555.
Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.
Dai M, Wang P, Boyd AD, et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 2005; 33: e175.

Auteurs

Moritz A Loeffler (MA)

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

Jun Hu (J)

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

Martina Kirchner (M)

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

Xiyang Wei (X)

Life Sciences Institute, Zhejiang University, Hangzhou, PR China.

Yi Xiao (Y)

Life Sciences Institute, Zhejiang University, Hangzhou, PR China.

Thomas Albrecht (T)

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

Carolina De La Torre (C)

Medical Research Centre, University of Heidelberg, Mannheim, Germany.

Carsten Sticht (C)

Medical Research Centre, University of Heidelberg, Mannheim, Germany.

Jesus M Banales (JM)

Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, San Sebastian, Spain.

Monika N Vogel (MN)

Diagnostic and Interventional Radiology, Thoraxklinik at University Hospital Heidelberg, Heidelberg, Germany.

Anita Pathil-Warth (A)

Department of Internal Medicine IV, Gastroenterology and Hepatology, University Hospital Heidelberg, Heidelberg, Germany.

Arianeb Mehrabi (A)

Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany.
Liver Cancer Center Heidelberg (LCCH), Heidelberg, Germany.

Katrin Hoffmann (K)

Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany.
Liver Cancer Center Heidelberg (LCCH), Heidelberg, Germany.

Christian Rupp (C)

Department of Internal Medicine IV, Gastroenterology and Hepatology, University Hospital Heidelberg, Heidelberg, Germany.
Liver Cancer Center Heidelberg (LCCH), Heidelberg, Germany.

Bruno Köhler (B)

Liver Cancer Center Heidelberg (LCCH), Heidelberg, Germany.
Department of Medical Oncology, University Hospital Heidelberg, National Center for Tumor Diseases, Heidelberg, Germany.

Christoph Springfeld (C)

Liver Cancer Center Heidelberg (LCCH), Heidelberg, Germany.
Department of Medical Oncology, University Hospital Heidelberg, National Center for Tumor Diseases, Heidelberg, Germany.

Peter Schirmacher (P)

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Liver Cancer Center Heidelberg (LCCH), Heidelberg, Germany.

Junfang Ji (J)

Life Sciences Institute, Zhejiang University, Hangzhou, PR China.

Stephanie Roessler (S)

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Liver Cancer Center Heidelberg (LCCH), Heidelberg, Germany.

Benjamin Goeppert (B)

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Liver Cancer Center Heidelberg (LCCH), Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH